secwatch.observer — SEC 8-K summary
======================================

Issuer:     Larimar Therapeutics, Inc. (LRMR)
CIK:        0001374690
Form:       8-K
Filed at:   2023-11-14T23:59:59+00:00
Accession:  0000950170-23-063347
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Larimar completes Phase 2 50mg cohort enrollment; top-line data now Q1 2024; cash to Q1 2025
--------------------------------------------------------------------------------

- Completed enrollment and dosing of 50 mg cohort in Phase 2 FA trial; no serious adverse events observed (blinded).
- Top-line safety, PK, and frataxin data now expected in Q1 2024, refined from H1 2024.
- Open-label extension trial with 25 mg daily nomlabofusp on track for Q1 2024; interim data expected Q4 2024.
- Cash, equivalents, and marketable securities of $95.6M as of Sep 30, 2023; projected runway into Q1 2025.
- Q3 2023 net loss $9.1M ($0.21/share) vs $8.3M ($0.37/share) in Q3 2022; R&D expenses up to $6.6M.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1374690/000095017023063347/0000950170-23-063347-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1374690/000095017023063347/lrmr-20231113.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-063347

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer